U.S. Markets closed

VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session

Zacks Equity Research
1 / 2

Is T. Rowe Price Mid-Cap Value Fund (TRMCX) a Strong Mutual Fund Pick Right Now?

Mutual Fund Report for TRMCX

VIVUS, Inc. VVUS was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $0.71-$0.84 in the past one-month time frame, showed a sharp increase yesterday.

The move came after the company issued favorable preliminary results from its Phase 1 clinical study.

The company has not seen any estimate revisions over the past month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

VIVUS currently has a Zacks Rank #3 (Hold), while its Earnings ESPis 0.00%.

VIVUS, Inc. Price and Consensus

VIVUS, Inc. Price and Consensus | VIVUS, Inc. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider Asterias Biotherapeutics, Inc. AST, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is VVUS going up? Or down? Predict to see what others think: Up or Down

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
VIVUS, Inc. (VVUS) : Free Stock Analysis Report
Asterias Biotherapeutics, Inc. (AST) : Free Stock Analysis Report
To read this article on Zacks.com click here.